HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
(Adnkronos) - CHENGDU, China, July 14, 2026 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), congratulates its partner BioAge Labs, Inc. ("BioAge"…
Read the full articleYou might also wanna read
Biogen defends anti-tau drug after stock slides on Alzheimer’s readout
Biogen leaders took to an investor call today to defend the phase 2 readout of the company’s anti-tau Alzheimer’s disease candidate, which d
AAIC: Biogen bolsters hopes for Alzheimer's pivotal push as anti-tau oligo slows cognitive decline
Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, backing up the pharm
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engager
Biogen (BIIB) Gains FDA Approval for Subcutaneous Alzheimer's Treatment Leqembi Iqlik
Related Stocks: BIIB
StudySetGo launches investor-company matchmaking platform
StudySetGo has launched a matchmaking platform connecting health and nutrition companies with investors to fund clinical trials, aiming to a
South Korea’s AimedBio Invests in Inocras, Partners on WGS for Cancer Trials
The companies hope to find patients likely to respond to AimedBio’s antibody-drug conjugates.
Comments
Sign in to join the conversation.
No comments yet. Be the first.